ATE250412T1 - Muskarinische antagonisten zur behandlung von presbyopie - Google Patents
Muskarinische antagonisten zur behandlung von presbyopieInfo
- Publication number
- ATE250412T1 ATE250412T1 AT99937295T AT99937295T ATE250412T1 AT E250412 T1 ATE250412 T1 AT E250412T1 AT 99937295 T AT99937295 T AT 99937295T AT 99937295 T AT99937295 T AT 99937295T AT E250412 T1 ATE250412 T1 AT E250412T1
- Authority
- AT
- Austria
- Prior art keywords
- presbyopia
- treatment
- muscarinic antagonists
- cholinergic
- restore
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
- 239000003149 muscarinic antagonist Substances 0.000 title 1
- 201000010041 presbyopia Diseases 0.000 title 1
- 230000004308 accommodation Effects 0.000 abstract 1
- 230000001713 cholinergic effect Effects 0.000 abstract 1
- 230000001886 ciliary effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000000472 muscarinic agonist Substances 0.000 abstract 1
- 230000001734 parasympathetic effect Effects 0.000 abstract 1
- 230000000284 resting effect Effects 0.000 abstract 1
- 230000036977 tonic contraction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/126,064 US6291466B1 (en) | 1998-07-30 | 1998-07-30 | Cholinergic agents in the treatment of presbyopia |
| PCT/US1999/016260 WO2000006135A2 (en) | 1998-07-30 | 1999-07-22 | Cholinergic agents in the treatment of presbyopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE250412T1 true ATE250412T1 (de) | 2003-10-15 |
Family
ID=22422802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99937295T ATE250412T1 (de) | 1998-07-30 | 1999-07-22 | Muskarinische antagonisten zur behandlung von presbyopie |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6291466B1 (de) |
| EP (1) | EP1100480B1 (de) |
| JP (1) | JP2002521429A (de) |
| KR (1) | KR20010079593A (de) |
| CN (1) | CN1157186C (de) |
| AT (1) | ATE250412T1 (de) |
| AU (1) | AU754588B2 (de) |
| BR (1) | BR9912599A (de) |
| CA (1) | CA2339093A1 (de) |
| DE (1) | DE69911620T2 (de) |
| ES (1) | ES2207963T3 (de) |
| WO (1) | WO2000006135A2 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX357548B (es) | 2006-07-11 | 2018-07-13 | Refocus Group Inc Star | Prótesis escleral para tratar presbiopia y otros trastornos del ojo y dispositivos y métodos relacionados. |
| US8911496B2 (en) | 2006-07-11 | 2014-12-16 | Refocus Group, Inc. | Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods |
| ATE439863T1 (de) * | 2006-12-18 | 2009-09-15 | Jorge Luis Benozzi | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie |
| GB0711151D0 (en) * | 2007-06-11 | 2007-07-18 | Sra Dev Ltd | Switch for use with an ultrasonic surgical tool |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| JP2013513622A (ja) * | 2009-12-14 | 2013-04-22 | ユニバーシティ オブ マサチューセッツ | 白内障及び老眼を阻害する方法 |
| CN103561748A (zh) * | 2011-04-07 | 2014-02-05 | 苏坎波公司 | 治疗眼疲劳的方法 |
| IN2014CN02961A (de) | 2011-09-20 | 2015-07-03 | Altavista Inst De Invest Medica S A S | |
| US9789091B2 (en) | 2013-03-14 | 2017-10-17 | University Of Massachusetts | Methods of inhibiting cataracts and presbyopia |
| US10307408B2 (en) | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
| US9833441B2 (en) | 2013-08-28 | 2017-12-05 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9844537B2 (en) | 2013-08-28 | 2017-12-19 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US11179327B2 (en) | 2013-08-28 | 2021-11-23 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| US10617763B2 (en) | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
| US10064818B2 (en) | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| EP3104851A1 (de) * | 2014-02-11 | 2016-12-21 | Orasis Pharmaceuticals Ltd. | Ophthalmische pharmakologische zusammensetzung zur verwendung bei der korrektur von altersweitsichtigkeit und dessen verabreichung |
| US12653779B2 (en) | 2015-06-18 | 2026-06-16 | Lenz Therapeutics Operations, Inc. | Compositions and methods for the treatment of presbyopia |
| CA2987787C (en) | 2015-06-18 | 2023-06-27 | Presbyopia Therapies, LLC | Compositions for the improvement of distance vision and the treatment of refractive errors of the eye |
| PE20181070A1 (es) | 2015-11-13 | 2018-07-04 | Univ Massachusetts | Moleculas bifuncionales que contienen peg para uso en la inhibicion de cataratas y presbicia |
| CH711969A2 (it) * | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
| KR102472774B1 (ko) | 2016-08-19 | 2022-11-30 | 오라시스 파마슈티칼스 엘티디. | 안과용 약학 조성물 및 이와 관련된 용도 |
| BR112020009361A2 (pt) * | 2017-11-17 | 2020-10-13 | Cellix Bio Private Limited | composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto |
| JP6946575B2 (ja) | 2018-04-24 | 2021-10-06 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 眼の状態の治療のためのピロカルピン塩酸塩の使用 |
| US20210369686A1 (en) * | 2018-10-06 | 2021-12-02 | Biotheravision Llc | Ophthalmic preparations of muscarinic agonist and methods of use |
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| BR112021006618B1 (pt) | 2018-10-10 | 2022-09-27 | Presbyopia Therapies, Inc | Composições e métodos para o tratamento da presbiopia |
| DK3870170T3 (da) | 2018-10-26 | 2026-05-26 | Opus Genetics Inc | Behandling af presbyopi og mydriasis med fentolamin |
| CN110496215A (zh) * | 2019-08-23 | 2019-11-26 | 中国人民解放军总医院 | 一种治疗老视的水性滴眼液及其制备方法 |
| BR112022026911A2 (pt) * | 2020-09-11 | 2023-03-28 | Intratus Nevada Inc | Composições e métodos para tratar presbiopia, hipermetropia, astigmatismo, diminuição da estereopsia e diminuição da sensibilidade ao contraste |
| KR20230087514A (ko) * | 2020-10-14 | 2023-06-16 | 산텐 세이야꾸 가부시키가이샤 | 안정한 의약 조성물 |
| WO2023091439A1 (en) | 2021-11-17 | 2023-05-25 | Lenz Therapeutics, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| US20230263727A1 (en) | 2022-01-14 | 2023-08-24 | Somerset Therapeutics, Llc | Ophthalmologically suitable low pka buffer-containing pilocarpine compositions and related methods |
| US11969410B2 (en) | 2022-02-09 | 2024-04-30 | Somerset Therapeutics, Llc | Low pH pilocarpine and brimonidine compound formulations and related methods |
| JPWO2023190653A1 (de) * | 2022-03-30 | 2023-10-05 | ||
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166317A (en) * | 1988-10-31 | 1992-11-24 | Houston Biotechnology Incorporated | Neurotrophic factor |
| FR2638970A1 (fr) | 1988-11-16 | 1990-05-18 | Corbiere Jerome | Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention |
| ATE183085T1 (de) | 1989-06-21 | 1999-08-15 | Univ Pennsylvania | Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten |
| US5122522A (en) * | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
| JPH07508751A (ja) | 1992-07-02 | 1995-09-28 | テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド | 老視治療のための方法および生産品 |
-
1998
- 1998-07-30 US US09/126,064 patent/US6291466B1/en not_active Expired - Lifetime
-
1999
- 1999-07-22 KR KR1020017001311A patent/KR20010079593A/ko not_active Ceased
- 1999-07-22 CA CA002339093A patent/CA2339093A1/en not_active Abandoned
- 1999-07-22 DE DE69911620T patent/DE69911620T2/de not_active Expired - Fee Related
- 1999-07-22 EP EP99937295A patent/EP1100480B1/de not_active Expired - Lifetime
- 1999-07-22 CN CNB998090514A patent/CN1157186C/zh not_active Expired - Fee Related
- 1999-07-22 BR BR9912599-4A patent/BR9912599A/pt not_active IP Right Cessation
- 1999-07-22 AU AU52160/99A patent/AU754588B2/en not_active Ceased
- 1999-07-22 JP JP2000561990A patent/JP2002521429A/ja active Pending
- 1999-07-22 WO PCT/US1999/016260 patent/WO2000006135A2/en not_active Ceased
- 1999-07-22 ES ES99937295T patent/ES2207963T3/es not_active Expired - Lifetime
- 1999-07-22 AT AT99937295T patent/ATE250412T1/de not_active IP Right Cessation
-
2001
- 2001-04-25 US US09/842,299 patent/US6410544B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002521429A (ja) | 2002-07-16 |
| AU5216099A (en) | 2000-02-21 |
| BR9912599A (pt) | 2001-05-02 |
| DE69911620D1 (de) | 2003-10-30 |
| US6410544B1 (en) | 2002-06-25 |
| EP1100480B1 (de) | 2003-09-24 |
| CN1157186C (zh) | 2004-07-14 |
| WO2000006135A2 (en) | 2000-02-10 |
| EP1100480A2 (de) | 2001-05-23 |
| HK1035493A1 (en) | 2001-11-30 |
| CA2339093A1 (en) | 2000-02-10 |
| WO2000006135A3 (en) | 2000-03-23 |
| AU754588B2 (en) | 2002-11-21 |
| CN1311670A (zh) | 2001-09-05 |
| KR20010079593A (ko) | 2001-08-22 |
| US6291466B1 (en) | 2001-09-18 |
| DE69911620T2 (de) | 2004-07-29 |
| ES2207963T3 (es) | 2004-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69911620D1 (de) | Muskarinische antagonisten zur behandlung von presbyopie | |
| ATE207356T1 (de) | Verwendung von tiagabin zur behandlung von schlafstörungen | |
| ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| DE69739792D1 (de) | Verfahren zur Behandlung von Augenerkrankungen | |
| NO992755D0 (no) | Protese for °yets senehinne for behandling av presbyopi og andre forstyrrelser i °yner | |
| DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
| DE10199020I2 (de) | Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit. | |
| ATE361752T1 (de) | Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen | |
| ATE213411T1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| NZ334063A (en) | use of a combination of a histamine H1 receptor antagonist and a histamine H3 receptor antagonist to treat upper airway allergic responses | |
| DE69738667D1 (de) | Vorbeugung und behandlung von kolonadenom oder kolonmikroadenom mit 6-fluorursodeoxycholsäure | |
| ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| ATE304886T1 (de) | Oxazolidinones zur behandlung von augeninfektionen | |
| DE69613041D1 (de) | Verwendung von Erdalkalimetalsalzen in Mitteln zur Behandlung van Augen- oder Augenlidschmerzen oder Dysesthesien | |
| DE59907195D1 (de) | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs | |
| DE69721747D1 (de) | Methode zur behandlung oder verhütung von interstitieller blasenentzundung | |
| ATE294584T1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
| PT1007093E (pt) | Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas | |
| ATE222768T1 (de) | Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen | |
| EP0329948A3 (de) | Verwendung von Betablockern zur Behandlung der Progression der kindlichen Achsenmyopie | |
| ATE262362T1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
| ATE369143T1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
| NO984196L (no) | FremgangsmÕte for behandling av stoffmisbruk | |
| DE69635282D1 (de) | Behandlung der exzessiven aggressivität mit olanzapine | |
| ATE225181T1 (de) | Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |